Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy

Jason Gillman, Patrick Janulis, Roy Gulick, Carole L. Wallis, Baiba Berzins, Roger Bedimo, Kimberly Smith, Michael Aboud, Babafemi Taiwo

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: To expand understanding of the virological potency of initial dolutegravir plus lamivudine dual therapy (dolutegravir/lamivudine), we compared the viral decay seen in the pilot ACTG A5353 study with the decay observed with dolutegravir plus two NRTIs in the SPRING-1 and SINGLE studies, while also exploring the impact of baseline viral load (VL). METHODS: Change in VL from baseline was calculated for timepoints shared by A5353 (n = 120, including 37 participants with pretreatment VL >100000 copies/mL), SPRING-1 (n = 51) and SINGLE (n = 417). The 95% CIs of change from baseline were determined for each observed week, using the mean log10-transformed VL, and compared between the dolutegravir/lamivudine and triple therapy groups using the Wilcoxon Rank Sum test for non-inferiority (δ = 0.5). To assess the impact of baseline VL on viral decay, we examined a bi-exponential non-linear mixed-effect model. RESULTS: The mean VL change from baseline to week 24 was -2.9 log10 copies/mL for dolutegravir/lamivudine versus -3.0 log10 copies/mL for dolutegravir-based three-drug therapy (P < 0.001). In the decay model, baseline VL >100000 copies/mL was associated with a slower initial decay rate (d1). A faster initial decay rate was seen with dolutegravir/lamivudine, which was partially offset when baseline VL was >100000 copies/mL as indicated by a significant interaction between baseline VL and drug therapy group. The secondary decay rate (d2) was not significantly different from zero, with no significant associations. CONCLUSIONS: Viral decay with dolutegravir/lamivudine was comparable to viral decay with dolutegravir-based triple therapy, even in individuals with higher pretreatment VL (>100000 copies/mL).

Original languageEnglish (US)
Pages (from-to)2365-2369
Number of pages5
JournalThe Journal of antimicrobial chemotherapy
Volume74
Issue number8
DOIs
StatePublished - Aug 1 2019
Externally publishedYes

Fingerprint

Lamivudine
Viral Load
Therapeutics
Nonparametric Statistics
dolutegravir
Drug Therapy
Group Psychotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. / Gillman, Jason; Janulis, Patrick; Gulick, Roy; Wallis, Carole L.; Berzins, Baiba; Bedimo, Roger; Smith, Kimberly; Aboud, Michael; Taiwo, Babafemi.

In: The Journal of antimicrobial chemotherapy, Vol. 74, No. 8, 01.08.2019, p. 2365-2369.

Research output: Contribution to journalArticle

Gillman, J, Janulis, P, Gulick, R, Wallis, CL, Berzins, B, Bedimo, R, Smith, K, Aboud, M & Taiwo, B 2019, 'Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy', The Journal of antimicrobial chemotherapy, vol. 74, no. 8, pp. 2365-2369. https://doi.org/10.1093/jac/dkz190
Gillman, Jason ; Janulis, Patrick ; Gulick, Roy ; Wallis, Carole L. ; Berzins, Baiba ; Bedimo, Roger ; Smith, Kimberly ; Aboud, Michael ; Taiwo, Babafemi. / Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. In: The Journal of antimicrobial chemotherapy. 2019 ; Vol. 74, No. 8. pp. 2365-2369.
@article{40110d7102a84b0a84af754750b48250,
title = "Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy",
abstract = "OBJECTIVES: To expand understanding of the virological potency of initial dolutegravir plus lamivudine dual therapy (dolutegravir/lamivudine), we compared the viral decay seen in the pilot ACTG A5353 study with the decay observed with dolutegravir plus two NRTIs in the SPRING-1 and SINGLE studies, while also exploring the impact of baseline viral load (VL). METHODS: Change in VL from baseline was calculated for timepoints shared by A5353 (n = 120, including 37 participants with pretreatment VL >100000 copies/mL), SPRING-1 (n = 51) and SINGLE (n = 417). The 95{\%} CIs of change from baseline were determined for each observed week, using the mean log10-transformed VL, and compared between the dolutegravir/lamivudine and triple therapy groups using the Wilcoxon Rank Sum test for non-inferiority (δ = 0.5). To assess the impact of baseline VL on viral decay, we examined a bi-exponential non-linear mixed-effect model. RESULTS: The mean VL change from baseline to week 24 was -2.9 log10 copies/mL for dolutegravir/lamivudine versus -3.0 log10 copies/mL for dolutegravir-based three-drug therapy (P < 0.001). In the decay model, baseline VL >100000 copies/mL was associated with a slower initial decay rate (d1). A faster initial decay rate was seen with dolutegravir/lamivudine, which was partially offset when baseline VL was >100000 copies/mL as indicated by a significant interaction between baseline VL and drug therapy group. The secondary decay rate (d2) was not significantly different from zero, with no significant associations. CONCLUSIONS: Viral decay with dolutegravir/lamivudine was comparable to viral decay with dolutegravir-based triple therapy, even in individuals with higher pretreatment VL (>100000 copies/mL).",
author = "Jason Gillman and Patrick Janulis and Roy Gulick and Wallis, {Carole L.} and Baiba Berzins and Roger Bedimo and Kimberly Smith and Michael Aboud and Babafemi Taiwo",
year = "2019",
month = "8",
day = "1",
doi = "10.1093/jac/dkz190",
language = "English (US)",
volume = "74",
pages = "2365--2369",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy

AU - Gillman, Jason

AU - Janulis, Patrick

AU - Gulick, Roy

AU - Wallis, Carole L.

AU - Berzins, Baiba

AU - Bedimo, Roger

AU - Smith, Kimberly

AU - Aboud, Michael

AU - Taiwo, Babafemi

PY - 2019/8/1

Y1 - 2019/8/1

N2 - OBJECTIVES: To expand understanding of the virological potency of initial dolutegravir plus lamivudine dual therapy (dolutegravir/lamivudine), we compared the viral decay seen in the pilot ACTG A5353 study with the decay observed with dolutegravir plus two NRTIs in the SPRING-1 and SINGLE studies, while also exploring the impact of baseline viral load (VL). METHODS: Change in VL from baseline was calculated for timepoints shared by A5353 (n = 120, including 37 participants with pretreatment VL >100000 copies/mL), SPRING-1 (n = 51) and SINGLE (n = 417). The 95% CIs of change from baseline were determined for each observed week, using the mean log10-transformed VL, and compared between the dolutegravir/lamivudine and triple therapy groups using the Wilcoxon Rank Sum test for non-inferiority (δ = 0.5). To assess the impact of baseline VL on viral decay, we examined a bi-exponential non-linear mixed-effect model. RESULTS: The mean VL change from baseline to week 24 was -2.9 log10 copies/mL for dolutegravir/lamivudine versus -3.0 log10 copies/mL for dolutegravir-based three-drug therapy (P < 0.001). In the decay model, baseline VL >100000 copies/mL was associated with a slower initial decay rate (d1). A faster initial decay rate was seen with dolutegravir/lamivudine, which was partially offset when baseline VL was >100000 copies/mL as indicated by a significant interaction between baseline VL and drug therapy group. The secondary decay rate (d2) was not significantly different from zero, with no significant associations. CONCLUSIONS: Viral decay with dolutegravir/lamivudine was comparable to viral decay with dolutegravir-based triple therapy, even in individuals with higher pretreatment VL (>100000 copies/mL).

AB - OBJECTIVES: To expand understanding of the virological potency of initial dolutegravir plus lamivudine dual therapy (dolutegravir/lamivudine), we compared the viral decay seen in the pilot ACTG A5353 study with the decay observed with dolutegravir plus two NRTIs in the SPRING-1 and SINGLE studies, while also exploring the impact of baseline viral load (VL). METHODS: Change in VL from baseline was calculated for timepoints shared by A5353 (n = 120, including 37 participants with pretreatment VL >100000 copies/mL), SPRING-1 (n = 51) and SINGLE (n = 417). The 95% CIs of change from baseline were determined for each observed week, using the mean log10-transformed VL, and compared between the dolutegravir/lamivudine and triple therapy groups using the Wilcoxon Rank Sum test for non-inferiority (δ = 0.5). To assess the impact of baseline VL on viral decay, we examined a bi-exponential non-linear mixed-effect model. RESULTS: The mean VL change from baseline to week 24 was -2.9 log10 copies/mL for dolutegravir/lamivudine versus -3.0 log10 copies/mL for dolutegravir-based three-drug therapy (P < 0.001). In the decay model, baseline VL >100000 copies/mL was associated with a slower initial decay rate (d1). A faster initial decay rate was seen with dolutegravir/lamivudine, which was partially offset when baseline VL was >100000 copies/mL as indicated by a significant interaction between baseline VL and drug therapy group. The secondary decay rate (d2) was not significantly different from zero, with no significant associations. CONCLUSIONS: Viral decay with dolutegravir/lamivudine was comparable to viral decay with dolutegravir-based triple therapy, even in individuals with higher pretreatment VL (>100000 copies/mL).

UR - http://www.scopus.com/inward/record.url?scp=85070118068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070118068&partnerID=8YFLogxK

U2 - 10.1093/jac/dkz190

DO - 10.1093/jac/dkz190

M3 - Article

C2 - 31039247

AN - SCOPUS:85070118068

VL - 74

SP - 2365

EP - 2369

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 8

ER -